853-P: Efficacy and Safety of HD-6277, a Novel GPR40 Agonist, in Patients with Type 2 Diabetes—A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Phase 2 Trial

Objective: To assess the efficacy and safety of HD-6277, the first candidate of GPR40 in a new oral antidiabetic agent, in Adult Patients With Inadequate Control of Type 2 Diabetes Mellitus (T2DM) Research Design & Methods: A double-blind, randomized, placebo-controlled phase 2 trial recruited 1...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes (New York, N.Y.) N.Y.), 2024-06, Vol.73 (Supplement_1), p.1
Hauptverfasser:	LEE, YONG-HO, MIN, KYUNGWAN, HWA HONG, JUN, LIM, SOO, YU, JAEMYUNG, CHUNG, CHOON H., SUNG MOON, JUN, CHUL WON, JONG, WOO AHN, CHUL, LEE, JIE-EUN, NYUN KIM, TAE, LEE, BYUNG-WAN
Format:	Artikel
Sprache:	eng
Schlagworte:	Agonists Blood levels Diabetes Diabetes mellitus (non-insulin dependent) Diet Fasting Homeostasis Placebos Statistical analysis
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!